Researchers conducted a retrospective analysis to identify seasonal variations in outcomes for COPD exacerbation admissions and the effect on healthcare resource utilization.
In patients with COPD, revefenacin demonstrated a safety profile similar to that of formoterol alone when given either before or combined with formoterol through a standard jet nebulizer.
Patients with COPD who have suboptimal peak inspiratory flow rate tend to have longer disease duration, be more symptomatic, have more severe airflow obstruction, and lower lung function, weight, and BMI.